PT - JOURNAL ARTICLE AU - Frederikus A. Klok AU - Volker Hösel AU - Andreas Clemens AU - Wilfrid D. Yollo AU - Clemens Tilke AU - Sam Schulman AU - Mareike Lankeit AU - Stavros V. Konstantinides TI - Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment AID - 10.1183/13993003.00280-2016 DP - 2016 Nov 01 TA - European Respiratory Journal PG - 1369--1376 VI - 48 IP - 5 4099 - http://erj.ersjournals.com/content/48/5/1369.short 4100 - http://erj.ersjournals.com/content/48/5/1369.full SO - Eur Respir J2016 Nov 01; 48 AB - Attempts at identifying patients with an elevated risk of bleeding while on anticoagulation following acute venous thromboembolism (VTE) have largely been unsuccessful thus far. We sought to develop a clinical prediction score for bleeding during stable anticoagulation treatment after acute VTE.We performed a post hoc analysis of the pooled RE-COVER studies, two double-blind randomised “sister” trials evaluating dabigatran versus standard treatment in 5107 VTE patients.A score was derived from patients randomised to dabigatran using logistic regression analysis covering the complete follow-up period. The final model, named VTE-BLEED, included six variables and yielded a c-statistic of 0.72 (95% CI 0.67–0.76). Patients from the derivation cohort in the low-risk group (<2 points; 74% of the derivation population) had a bleeding incidence of 2.8% compared to 12.6% in the elevated-risk group (OR 5.0; 95% CI 3.5–7.1). The score proved accurate for our primary end-point, i.e. prediction of major bleeding after day 30 (“stable” anticoagulation), both in patients on dabigatran (c-statistic 0.75, 95% CI 0.61–0.89) and those on warfarin (0.78, 95% CI 0.68–0.86; p=0.77 for difference).The new VTE-BLEED score accurately predicted major bleeding events in VTE patients on stable anticoagulation with both dabigatran and warfarin.The new VTE-BLEED score predicted major bleeding events in VTE patients on stable anticoagulation treatment http://ow.ly/TxED300SpwI